Login / Signup

Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.

Sonya C Tang GirdwoodDenise HassonJ Timothy CaldwellCara SlagleShun DongLin FeiPeter TangAlexander A VinksJennifer KaplanStuart L Goldstein
Published in: The Journal of antimicrobial chemotherapy (2023)
We show a relationship between estimated piperacillin AUC and highest Cmin in the first 24 hours of piperacillin/tazobactam therapy and piperacillin-associated AKI, suggesting total piperacillin exposure early in the course is associated with AKI development. These data could serve as the foundation for implementation of model-informed precision dosing to reduce AKI incidence in patients given piperacillin/tazobactam.
Keyphrases